Refractory small molecules are often a barrier to translation due to their low solubility, low bioavailability, and formulation challenges. Nanocrystallization is a versatile approach to salvage refractory drugs with the added advantage of carrier-free delivery systems.
Protheragen-ING specializes in providing cutting-edge nanocrystal development services to help clients rescue hydrophobic drugs through nanocrystal formulation approaches. Depending on the disease, customized formulations can be administered via different routes, including oral, transdermal, and parenteral. This highlights the versatility of the nanocrystal drug platform. Our team of experienced scientists and engineers can assist you at every stage of the development process.
Drug nanocrystals can be defined as pure solid particles with an average diameter <1 μm and crystalline characteristics. This platform provides an excellent opportunity to deliver hydrophobic drugs. It is unique in that the nanocrystals consist entirely of 100% drug or payload, thus eliminating the role of carrier assistance.
Fig. 1 Nanocrystallization of poorly soluble drugs improves physicochemical stability and drug bioavailability. (Jarvis M, et al. 2019)
Nanocrystal drug technology improves the solubility of hydrophobic drugs due to an increase in the surface area to volume ratio as well as an increase in the dissolution rate associated with the nano-size. The drug crystals are particularly suitable for the repair of Biopharmaceutics Classification System (BCS) Class II and IV drugs (low solubility drugs).
Nanocrystalline drug formulations have also been shown to be stable in suspensions, often referred to as nanocrystalline colloidal dispersions (NCDs), allowing for easy scale-up and manufacture of highly stable and marketable products.
We can help develop a variety of nanocrystalline materials with different surface charges for drug delivery purposes.
Type of Nanocrystal | Preclinical Model (In Vitro) | Surface Charges |
---|---|---|
Magnetite | HCT116 | Neutral |
NIH3T3 | ||
SPIONSa | HUVEC | +9.4 mV, −8.3 mV |
MCF7 | ||
Cellulose‐FITC | HEK 293 | +3.9 mV, −46.4 mV, −48.7 mV |
Cellulose‐RBITC | Sf9 | +9.0 mV, 8.7 mV, 8.6 mV |
Cellulose | KU‐7 | 0 mV to −55 mV |
Cellulose | MDCK, HeLa | −40 mV to 100 mV |
Caco-2, J774 | ||
Camptothecin | Eahy926 | −4.67 mV, −9.66 mV, −30.4 mV |
Paclitaxel | A549 | +19.3 mV, −2.4 mV, −22.7 mV |
Paclitaxel | MCF-7 | −2.73 mV, −15.9 mV, −16.6 mV |
HaCaT | ||
Hydroxyapatite | MC3T3-E1 | −12.5 mV, −23.3 mV |
Hydroxyapatite | MC3T3-E1 | +48.6 mV, −11.4 mV, −28.3 mV |
NC‐quantum dots | Vero | +40.52 mV, +36.2 mV, −48.12 mV |
CdSe quantum | NHBE cells | −21 mV, −53.5 mV, −71.8 mV |
Dot NC-MUA ligand | ||
CdSe quantum | NHBE cells | −29.4 mV, −39 mV, −56 mV |
Dot NC-MPA ligand | ||
CdSe quantum | NHBE cells | +86.8 mV, 73.7 mV, 60.6 mV |
Dot NC-AUT ligand | ||
CdSe quantum | NHBE cells | +57.4 mV, 46.7 mV, 43.4 mV |
Dot NC-CYST ligand |
Top-down approaches: High‐pressure homogenization (HPH), and Media milling (MM)
Bottom-up approach: Precipitation
Combined approach
New microfluidic technique
Fig. 2 Main nanocrystal production techniques. (Zingale E, et al. 2022)
Contact us today to discuss your nanocrystal development needs and discover how our services can accelerate your research, development, and innovation efforts. Let Protheragen-ING be your trusted partner in unlocking the potential of nanotechnology.
References
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed